Verlag: Chapman and Hall/CRC (edition 1), 2021
ISBN 10: 1032242647 ISBN 13: 9781032242644
Sprache: Englisch
Anbieter: BooksRun, Philadelphia, PA, USA
Paperback. Zustand: Good. 1. It's a preowned item in good condition and includes all the pages. It may have some general signs of wear and tear, such as markings, highlighting, slight damage to the cover, minimal wear to the binding, etc., but they will not affect the overall reading experience.
Anbieter: Books From California, Simi Valley, CA, USA
paperback. Zustand: Fine.
Hardcover. Zustand: As New. No Jacket. Pages are clean and are not marred by notes or folds of any kind. ~ ThriftBooks: Read More, Spend Less 1.35.
Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes Königreich
EUR 54,88
Anzahl: 10 verfügbar
In den WarenkorbZustand: As New. Unread book in perfect condition.
Anbieter: THE SAINT BOOKSTORE, Southport, Vereinigtes Königreich
EUR 63,11
Anzahl: 1 verfügbar
In den WarenkorbPaperback / softback. Zustand: New. New copy - Usually dispatched within 4 working days.
Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes Königreich
EUR 63,10
Anzahl: 10 verfügbar
In den WarenkorbZustand: New.
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 71,30
Anzahl: 1 verfügbar
In den WarenkorbPaperback. Zustand: Brand New. 1st edition. 309 pages. 9.25x6.25x0.50 inches. In Stock.
EUR 59,53
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. Ying Yuan is a professor and co-chief of the Section of Adaptive Clinical Trials in the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. He is also an adjunct associate professor in the Department of Stat.
EUR 129,26
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New.
Anbieter: Best Price, Torrance, CA, USA
Zustand: New. SUPER FAST SHIPPING.
Anbieter: Lucky's Textbooks, Dallas, TX, USA
EUR 131,45
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New.
Taschenbuch. Zustand: Neu. Neuware - This book is the first to focus on Bayesian phase I-II clinical trials. It describes many problems with the conventional phase I-phase II paradigm and covers a large number of modern Bayesian phase I-II clinical trial designs.
Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes Königreich
EUR 128,43
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New.
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
EUR 138,70
Anzahl: 3 verfügbar
In den WarenkorbZustand: New.
Anbieter: THE SAINT BOOKSTORE, Southport, Vereinigtes Königreich
EUR 128,45
Anzahl: 1 verfügbar
In den WarenkorbHardback. Zustand: New. New copy - Usually dispatched within 4 working days. 652.
Zustand: New.
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
EUR 142,62
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. In.
Anbieter: Biblios, Frankfurt am main, HESSE, Deutschland
Zustand: New.
Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes Königreich
EUR 199,45
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: As New. Unread book in perfect condition.
Anbieter: Mispah books, Redhill, SURRE, Vereinigtes Königreich
EUR 190,13
Anzahl: 1 verfügbar
In den WarenkorbHardcover. Zustand: Like New. Like New. book.
EUR 223,40
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: As New. Unread book in perfect condition.
Anbieter: PBShop.store UK, Fairford, GLOS, Vereinigtes Königreich
EUR 148,26
Anzahl: Mehr als 20 verfügbar
In den WarenkorbHRD. Zustand: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Anbieter: PBShop.store US, Wood Dale, IL, USA
EUR 155,03
Anzahl: Mehr als 20 verfügbar
In den WarenkorbHRD. Zustand: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Buch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources. Bayesian Designs for Phase I-II Clinical Trials describes how phase I-II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes.Written by research leaders from the University of Texas MD Anderson Cancer Center, this book shows how Bayesian designs for early-phase clinical trials can explore, refine, and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity. 324 pp. Englisch.
Anbieter: moluna, Greven, Deutschland
EUR 119,01
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Ying Yuan is a professor and co-chief of the Section of Adaptive Clinical Trials in the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. He is also an adjunct associate professor in the Department of Stat.
Anbieter: THE SAINT BOOKSTORE, Southport, Vereinigtes Königreich
EUR 160,26
Anzahl: Mehr als 20 verfügbar
In den WarenkorbHardback. Zustand: New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days.
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources. Bayesian Designs for Phase I-II Clinical Trials describes how phase I-II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes.Written by research leaders from the University of Texas MD Anderson Cancer Center, this book shows how Bayesian designs for early-phase clinical trials can explore, refine, and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity.